The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Prior to publication of each Guideline, a Call for Comment phase is opened available only for SITC members to review a draft copy of the Guideline and provide feedback in the goal of further improving the draft. Click here to learn more about the Call for Comment process.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Published August 27, 2013 in Nature Reviews Clinical Oncology as "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma."
An update to the Melanoma Guidelines is expected to be published in 2017.
Published November 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of academic physicians and researchers,nurses, patients, and patient advocates invited from a diversity of institutions across the United States.
Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.
We have a patient with multiple brain metastases from melanoma beginning to develop symptoms (mental slowing and right facial droop) as we try to get him precerted for checkpoint inhibitor therapy. Any thoughts/anecdotes/data about how much if any ...
Did you know there are more than 800 resources available to SITC members? Access by your user type ( researcher , clinician , patient ) or by using the SITC Cancer Immunotherapy CONNECT Search (top right) to find exactly what you're looking ...
In light of what can occur in the TME in the steady state, malignant cells killed by intrinsic/extrincic stress factors in it can lead to danger-associated molecular patterns (e.g. HMGB-1) and plasma membrane exposure of the endoplasmic reticulum (ER) ...
Thank you everyone.Very helpful. ------------------------------ Jane Gutkovich Director of Research The EHE Foundation Woodbridge VA ------------------------------
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com